AstraZeneca has ended a phase 3 clinical trial of the drug volrustomig for the treatment of metastatic non-small cell lung cancer.
The trial was specifically evaluating the drug in combination with chemotherapy compared to pembrolizumab and chemotherapy in metastatic non-small cell lung cancer patients whose PD-L1 scores were less than 50%, according to an Aug. 17 news release from AstraZeneca.
After reviewing trial data, the Independent Data Monitoring Committee determined volrustomig was unlikely to meet survival outcomes, though no new safety signals were identified.
“While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines from our industry-leading pipeline in our quest to improve outcomes for patients with lung cancer,” Susan Galbraith, MD, PhD, executive vice president of oncology haematology R&D at AstraZeneca, said in the release.
Other phase 3 volrustomig trials in cervical cancer, head and neck squamous cell carcinoma and mesothelioma will continue as planned, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
